Cambium Bio (ASX:CMB) - Stock Price, News & Analysis

CMB Stock Overview

Cambium Bio Limited operates as a clinical-stage regenerative medicine company.

CMB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (A$9M)

Cambium Bio Limited Competitors

Exopharm

ASX:EX1

AU$4.8m

NeuroScientific Biopharmaceuticals

ASX:NSB

AU$6.9m

Anatara Lifesciences

ASX:ANR

AU$8.2m

Nanollose

ASX:NC6

AU$3.4m

Price History & Performance

Summary of all time highs, changes and price drops for Cambium Bio
Historical stock prices
Current Share Price	AU$0.013
52 Week High	AU$0
52 Week Low	AU$0
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-7.14%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	CMB	AU Biotechs	AU Market
7D	n/a	-0.4%	-0.3%
1Y	n/a	-7.3%	6.1%

Return vs Industry: Insufficient data to determine how CMB performed against the Australian Biotechs industry.

Return vs Market: Insufficient data to determine how CMB performed against the Australian Market.

Price Volatility

Is CMB's price volatile compared to industry and market?
CMB volatility
CMB Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.0%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: CMB has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CMB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	n/a	Terence Walts	regeneus.com.au

Regeneus Ltd operates as a clinical-stage regenerative medicine company. The company uses stem cell technologies to develop a portfolio of novel cell-based therapies. Its regenerative platform technologies Progenza and Sygenus address unmet medical needs in human health markets, focusing on neuropathic pain, osteoarthritis, and various skin conditions.

Cambium Bio Limited Fundamentals Summary

How do Cambium Bio's earnings and revenue compare to its market cap?
CMB fundamental statistics
Market cap	AU$8.58m
Earnings (TTM)	AU$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is CMB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMB income statement (TTM)
Revenue	AU$0
Cost of Revenue	AU$0
Gross Profit	AU$0
Other Expenses	AU$0
Earnings	AU$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did CMB perform over the long term?

See historical performance and comparison